CYP17 genetic polymorphism in patients with endometrial hyperplasia and cancer

Basit Öğe Kaydı
dc.contributor.authorAban, M
dc.contributor.authorArslan, M
dc.contributor.authorTok, E
dc.contributor.authorTekes, S
dc.contributor.authorBudak, T
dc.contributor.authorAltintas, A
dc.date.accessioned2024-04-24T17:11:36Z
dc.date.available2024-04-24T17:11:36Z
dc.date.issued2006
dc.departmentDicle Üniversitesien_US
dc.description.abstractWe investigated the association of CYP17 gene polymorphism with the risk of having endometrial cancer and a well-known precursor of it, endometrial hyperplasia. Group A (control group) consisted of 35 patients who had histologically proven normal endometrium. Group B and C consisted of 18 and 30 patients who had endometrial hyperplasia with and without atypia, respectively. Group D consisted of 57 patients who had endometrial cancer. Venous blood samples were collected from patients in groups, and polymerase chain reaction was performed to determine the CYP17 gene polymorphism. Significant increase of A1/A1 and a decrease of A1/A2 genotype frequencies have been determined in patients with endometrial cancer and with atypical endometrial hyperplasia. No significant differences were found between groups in the frequency of A2/A2 genotype. There was no significant difference between the groups in the meaning of allele distributions. CYP17 polymorphism had correlation with endometrial atypia and cancer. Related effects of different types of CYP17 gene variants on the progression of hyperplastic endometrial cells into carcinoma should be evaluated in further studies. Progress in this area would help us modulate preventive treatments used in those actual high-risk group patients.en_US
dc.identifier.doi10.1111/j.1525-1438.2006.00417.x
dc.identifier.endpage451en_US
dc.identifier.issn1048-891X
dc.identifier.issn1525-1438
dc.identifier.pmid16515644
dc.identifier.scopus2-s2.0-33645334674
dc.identifier.scopusqualityQ1
dc.identifier.startpage448en_US
dc.identifier.urihttps://doi.org/10.1111/j.1525-1438.2006.00417.x
dc.identifier.urihttps://hdl.handle.net/11468/17626
dc.identifier.volume16en_US
dc.identifier.wosWOS:000236269900085
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofInternational Journal of Gynecological Cancer
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCanceren_US
dc.subjectCyp17en_US
dc.subjectEndometriumen_US
dc.subjectGeneen_US
dc.subjectHyperplasiaen_US
dc.subjectPolymorphismen_US
dc.titleCYP17 genetic polymorphism in patients with endometrial hyperplasia and canceren_US
dc.titleCYP17 genetic polymorphism in patients with endometrial hyperplasia and cancer
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu